Zobrazeno 1 - 10
of 555
pro vyhledávání: '"EGFR-TKI resistance"'
Autor:
Liqun Li, Zhe Huang, Yangqian Chen, Hongzhi Ma, Xiaoquan Chen, Huan Yan, Haoyue Qin, Yuda Zhang, Xing Zhang, Wenjuan Jiang, Zhan Wang, Lin Zhang, Fanxu Zeng, Zhiguo Zhou, Xingxiang Pu, Nong Yang, Liang Zeng, Yongchang Zhang
Publikováno v:
Heliyon, Vol 10, Iss 24, Pp e40703- (2024)
Objective: This study assessed the impact of intrathecal pemetrexed (IP) in managing leptomeningeal metastases (LM) in previously treated patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC). Methods: We analyzed the clinical and sur
Externí odkaz:
https://doaj.org/article/b24b6128172e4930b3ab5ea5c74693cd
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Non-small cell lung cancer (NSCLC) is one of the most common malignancies in the world. EGFR tyrosine inhibitors are the preferred first-line treatment for patients with epidermal growth factor-cell receptor mutant (EGFR mutant) advanced NSCLC. Unfor
Externí odkaz:
https://doaj.org/article/c240e7fda61541daa0fbe059229966dc
Autor:
Weina Fan, Ying Xing, Shi Yan, Wei Liu, Jinfeng Ning, Fanglin Tian, Xin Wang, Yuning Zhan, Lixin Luo, Mengru Cao, Jian Huang, Li Cai
Publikováno v:
Cancer Cell International, Vol 24, Iss 1, Pp 1-19 (2024)
Abstract Background Lung adenocarcinoma (LUAD) patients have a dismal survival rate because of cancer metastasis and drug resistance. The study aims to identify the genes that concurrently modulate EMT, metastasis and EGFR-TKI resistance, and to inve
Externí odkaz:
https://doaj.org/article/aeee91a5a9284ceca2e6632d57eec117
Autor:
Li, Liqun a, b, 1, Huang, Zhe a, b, 1, Chen, Yangqian b, Ma, Hongzhi c, Chen, Xiaoquan a, Yan, Huan b, Qin, Haoyue b, Zhang, Yuda b, Zhang, Xing b, Jiang, Wenjuan b, Wang, Zhan b, Zhang, Lin c, Zeng, Fanxu b, Zhou, Zhiguo a, Pu, Xingxiang b, Yang, Nong b, Zeng, Liang b, ⁎⁎, Zhang, Yongchang b, d, ⁎
Publikováno v:
In Heliyon 30 December 2024 10(24)
Autor:
Kan Jiang, Lin Wu, Xinlong Zheng, Yiquan Xu, Qian Miao, Xiaobin Zheng, Longfeng Zhang, Cheng Huang, Gen Lin
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background Advanced lung adenocarcinoma patients often develop resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs), leaving uncertainties regarding subsequent treatment strategies. Although personalized therapy targeting individual acq
Externí odkaz:
https://doaj.org/article/cc9c753a114c4fb5838a49022edbbeb2
Autor:
Boyang Shi, Ke An, Yueqin Wang, Yuhan Fei, Caixia Guo, Qiangfeng Cliff Zhang, Yun-Gui Yang, Xin Tian, Quancheng Kan
Publikováno v:
Genomics, Proteomics & Bioinformatics, Vol 21, Iss 4, Pp 850-865 (2023)
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) positively affect the initial control of non-small cell lung cancer (NSCLC). Rapidly acquired resistance to EGFR-TKIs is a major hurdle in successful treatment. However, the mech
Externí odkaz:
https://doaj.org/article/c6e59523a7464d8bbc054b8c9402d7d1
Autor:
Juan Zhou, Xiangling Chu, Jing Zhao, Mengqing Xie, Jing Wu, Xin Yu, Yujia Fang, Yazhou Li, Xiyan Li, Chunxia Su
Publikováno v:
Biological Procedures Online, Vol 25, Iss 1, Pp 1-13 (2023)
Abstract Background Clinical studies suggest that immune checkpoint inhibitor (ICI) monotherapy has limited benefits in non-small cell lung cancer (NSCLC) patients after epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) failure. H
Externí odkaz:
https://doaj.org/article/67c780f444bc46258dd9398bbbe65e60
Autor:
Yen‐Ting Lin, Chao‐Chi Ho, Wei‐Hsun Hsu, Wei‐Yu Liao, Ching‐Yao Yang, Chong‐Jen Yu, Tzu‐Hsiu Tsai, James Chih‐Hsin Yang, Shang‐Gin Wu, Chia‐Lin Hsu, Min‐Shu Hsieh, Yen‐Lin Huang, Chia‐Ling Wu, Jin‐Yuan Shih
Publikováno v:
Cancer Medicine, Vol 13, Iss 1, Pp n/a-n/a (2024)
Abstract Introduction According to current International Association for the Study of Lung Cancer guideline, physicians may first use plasma cell‐free DNA (cfDNA) methods to identify epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
Externí odkaz:
https://doaj.org/article/16337db479754d2fa1ffefc1d301d9fd
Autor:
Dantong Sun, Feiyue Feng, Fei Teng, Tongji Xie, Jinsong Wang, Puyuan Xing, Haili Qian, Junling Li
Publikováno v:
Cell Communication and Signaling, Vol 21, Iss 1, Pp 1-16 (2023)
Abstract Introduction Dysregulated ARID1A expression is frequently detected in lung adenocarcinoma (LUAD) and mediates significant changes in cancer behaviors and a poor prognosis. ARID1A deficiency in LUAD enhances proliferation and metastasis, whic
Externí odkaz:
https://doaj.org/article/b44b859bf4da482ab95281c171696e57
Autor:
Filip Gorachinov, Fatima Mraiche, Diala Alhaj Moustafa, Ola Hishari, Yomna Ismail, Jensa Joseph, Maja Simonoska Crcarevska, Marija Glavas Dodov, Nikola Geskovski, Katerina Goracinova
Publikováno v:
Beilstein Journal of Nanotechnology, Vol 14, Iss 1, Pp 240-261 (2023)
Genomic and proteomic mutation analysis is the standard of care for selecting candidates for therapies with tyrosine kinase inhibitors against the human epidermal growth factor receptor (EGFR TKI therapies) and further monitoring cancer treatment eff
Externí odkaz:
https://doaj.org/article/4720eb222e7549458be181158a791d7b